Pre-made Sirukumab benchmark antibody ( Whole mAb, anti-IL6 therapeutic antibody, Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-525

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-525 Category Tag

Product Details

Pre-Made Sirukumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Products Name (INN Index)

Pre-Made Sirukumab biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 therapeutic antibody

INN Name

Sirukumab

Target

IL6

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2011

Companies

Centocor Inc,GlaxoSmithKline,Janssen Biotech

Conditions Approved

NA

Conditions Active

Giant cell arteritis,Asthma,Lupus nephritis,Major depressive disorder

Conditions Discontinued

Rheumatoid arthritis,Atherosclerosis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL6

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide